U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Links from BioSample

SRX7656770: GSM4292486: WT-Rituximab-Day4_rep1; Cricetulus griseus; RNA-Seq
4 ILLUMINA (NextSeq 500) runs: 19.3M spots, 5G bases, 2.1Gb downloads

Submitted by: NCBI (GEO)
Study: Multiplex secretome engineering enhances recombinant protein production and purity
show Abstracthide Abstract
Host cell proteins (HCPs) are process-related impurities generated during biotherapeutic protein production. HCPs can be problematic if they pose a significant metabolic demand, degrade product quality, or contaminate the final product. Here, we present an effort to create a “clean” Chinese hamster ovary (CHO) cell by disrupting multiple genes to eliminate HCPs. Using a model of CHO cell protein secretion, we predicted the elimination of unnecessary HCPs could have a non-negligible impact on protein production. We analyzed the total HCP content of 6-protein, 11-protein, and 14-protein knockout clones and characterized their growth in shake flasks and bioreactors. These cell lines exhibited a substantial reduction in total HCP content (40%-70%). We also observed higher productivity and improved growth characteristics, in specific clones. With the reduced HCP content, protein A and ion exchange chromatography more efficiently purified a monoclonal antibody (mAb) produced in these cells during a three-step purification process. Thus, substantial improvements can be made in protein titer and purity through large-scale HCP deletion, providing an avenue to increased quality and affordability of high-value biopharmaceuticals. Overall design: CHO-S cells were subjected to 4 cycles of CRISPR/Cas9-mediated multiplex gene disruption to produce 6-protein (BGN, TIMP1, LGALS3BP, NID1.1, NID1.2, and CTSD), 11-protein (BGN, TIMP1, LGALS3BP, NID1.1, NID1.2, CTSD, Aga, Erp29, Gpr56, Tinagl1, and Lgmn), and 14 protein (BGN, TIMP1, LGALS3BP, NID1.1, NID1.2, CTSD, Aga, Erp29, Gpr56, Tinagl1, Lgmn, Yeats2, Sparc, and Lpl) knockout strains. WT CHO-S and knockout cell lines (6x, 11x, and 14x) were transacted with a plasmid encoding the Rituximab antibody and the zeocin selection gene using Freestyle MAX reagent. The WT CHO-S, 6xKO and 11xKO strains were subjected to RNA-Seq at 3 different time points (4 days, 6 days, and 8 days). Library preparation was performed with Illumina's TruSeq Stranded mRNA Library Prep Kit High Throughput (Catalog ID: RS-122-2103).
Sample: WT-Rituximab-Day4_rep1
SAMN13957915 • SRS6086035 • All experiments • All runs
Library:
Instrument: NextSeq 500
Strategy: RNA-Seq
Source: TRANSCRIPTOMIC
Selection: cDNA
Layout: PAIRED
Construction protocol: Cell cultures were resuspended in RLT buffer (Qiagen) and kept at -80°C until RNA was extracted using the RNeasy kit (Qiagen) and on-column DNAse digestion. RNA was eluted in 40µl of nuclease free water (RNAse/DNAse free); concentration was measured on Qubit and the purity was checked on Fragment Analyzer. Complementary DNA synthesis was obtained from 1 μg of RNA using the High capacity cDNA RT kit (Thermo Fisher scientific) as per manufacturer's instructions. Samples were diluted to 60ng/µL in 50µL and library preparation was performed with Illumina's TruSeq Stranded mRNA Library Prep Kit High Throughput (Catalog ID: 20020595), according to manufacturer's protocol.
Experiment attributes:
GEO Accession: GSM4292486
Links:
Runs: 4 runs, 19.3M spots, 5G bases, 2.1Gb
Run# of Spots# of BasesSizePublished
SRR109956315,227,7061.4G548Mb2020-03-25
SRR109956324,766,4831.2G528.1Mb2020-03-25
SRR109956334,669,4101.2G538.3Mb2020-03-25
SRR109956344,597,7291.2G534.6Mb2020-03-25

ID:
9990678

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...